Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2551637 | 0.80 | ALDH1A1 (0.35) | ALDH1A1CYP1A2L3MBTL1CYP2A6 | |
| SCHEMBL2545821 | 0.80 | HTR2A (0.36) | ALDH1A1HSD17B10HIF1ACYP1B1GPR84 | |
| SCHEMBL2555038 | 0.77 | SMN1; SMN2 (0.35) | GPR84FFAR1TSHRSMN1; SMN2 | |
| SCHEMBL2548356 | 0.70 | TSHR (0.33) | HPGDTSHRSMN1; SMN2MAPT | |
| SCHEMBL2549210 | 0.70 | PPARG (0.42) | HIF1APPARGPPARACYP1A2TSHR | |
| SCHEMBL2551261 | 0.70 | ALDH1A1 (0.41) | ALDH1A1HSD17B10CYP1B1CYP1A2L3MBTL1 | |
| SCHEMBL8406649 | 0.68 | ALDH1A1 (0.50) | TRPM4ALDH1A1HSD17B10HIF1ACYP1B1 | |
| SCHEMBL2885129 | 0.68 | TRPM4 (0.38) | TRPM4ALDH1A1HSD17B10HIF1ACYP1B1 | |
| SCHEMBL27891609 | 0.68 | TRPM4 (0.35) | TRPM4ALDH1A1HSD17B10HIF1ACYP1B1 | |
| SCHEMBL2549105 | 0.68 | TRPM4 (0.35) | TRPM4ALDH1A1HSD17B10HIF1ACYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552928-B1 | A PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST. | CHROMAFORA AB (SE) | 2015-04-15 | — | — | EP | disclosed |
| US-8735629-B2 | Process for the reduction of a tertiary phosphine oxide to the corresponding tertiary phosphine in the presence of a catalyst and use of a tertiary phosphine for reducing a tertiary phosphine oxide in the presence of a catalyst | CHROMAFORA AB (SE) | 2014-05-27 | — | — | US | disclosed |
| US-8426647-B2 | — | — | 2013-04-23 | — | — | US | disclosed |
| EP-2552928-A1 | A PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST | Chromafora AB (SE) | 2013-02-06 | — | — | EP | disclosed |
| US-20130012725-A1 | PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST | CHROMAFORA AB (SE) | 2013-01-10 | — | — | US | disclosed |
| WO-2011123037-A1 | A PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST | CHROMAFORA AB (SE) | 2011-10-06 | — | — | WO | disclosed |
| US-7847126-B2 | prepared by reacting phosphorus halide with organomagnesium compound in presence of copper compound; di(tert-butyl)phenylphosphonium tetrafluoroborate, for example | LANXESS DEUTSCHLAND GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-20070299273-A1 | prepared by reacting phosphorus halide with organomagnesium compound in presence of copper compound; di(tert-butyl)phenylphosphonium tetrafluoroborate, for example | LANXESS DEUTSCHLAND GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
| US-7230136-B2 | Reacting phosphorus halide with organomagnesium compound in presence of copper compound | LANXESS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20030229240-A1 | Reacting phosphorus halide with organomagnesium compound in presence of copper compound | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| EP-1354886-A1 | Process for the preparation of tertiary phosphines | Bayer Aktiengesellschaft (DE) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012725-A1 | PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST | PSPH, PNPO, PHOSPHO1 | TRPM4 4136/4885ALDH1A1 2830/4885HSD17B10 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.